Hong Kong
# |
Name |
Shares (Diluted, Weighted) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
2,069,710,308
|
Dec. 31, 2023 | USD 0.22 | -1.18% |
|
Hong Kong |
|
2 |
1,018,115,585
|
Dec. 31, 2023 | USD 0.13 | -0.02% |
|
Hong Kong |
|
3 |
869,196,348
|
Dec. 31, 2023 | USD 2.68 | -1.44% |
|
Hong Kong |
|
4 |
588,836,000
|
Dec. 31, 2023 | USD 0.16 | -3.21% |
|
Hong Kong |
|
5 |
76,055,750
|
Dec. 31, 2023 | USD 0.37 | 4.31% |
|
Hong Kong |
|
6 |
13,012,866
|
June 30, 2024 | USD 3.80 | 0.53% |
|
Hong Kong |
|
7 |
11,246,010
|
Dec. 31, 2023 | USD 5.25 | -2.96% |
|
Hong Kong |
The Clinical Trials company in Hong Kong with the highest Shares (Diluted, Weighted) is Frontage Holdings Corporation (HKSE: 1521.HK) at 2,069,710,308.
The Clinical Trials company in Hong Kong with the lowest Shares (Diluted, Weighted) is Prenetics Global Limited (NasdaqGM: PRE) at 11,246,010.
The top 10 Clinical Trials companies in Hong Kong by Shares (Diluted, Weighted) are Frontage Holdings Corporation, SinoMab BioScience Limited, HUTCHMED (China) Limited, Lee's Pharmaceutical Holdings Limited, Sirnaomics Ltd., Regencell Bioscience Holdings Limited and Prenetics Global Limited.
The bottom 10 Clinical Trials companies in Hong Kong by Shares (Diluted, Weighted) are Prenetics Global Limited, Regencell Bioscience Holdings Limited, Sirnaomics Ltd., Lee's Pharmaceutical Holdings Limited, HUTCHMED (China) Limited, SinoMab BioScience Limited and Frontage Holdings Corporation.